Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
Follow HOWL
Werewolf Therapeutics, Inc. (HOWL) Altman Z-score
Werewolf Therapeutics, Inc.'s Altman Z-score for fiscal 2024 is −4.83, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −4.83 | (3.54) |
| FY2023 | −1.29 | 0.64 |
| FY2022 | −1.92 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.77 | — | 0.93 | |
| Retained earnings / total assets | (3.27) | — | −4.57 | |
| EBIT / total assets | (0.58) | — | −1.91 | |
| Market value of equity / total liabilities | 1.20 | — | 0.72 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −4.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −8.05 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ACET Adicet Bio, Inc. compare | 5.0× |
| IBIO iBio, Inc. compare | 2.8× |
| ELTX Elicio Therapeutics, Inc. compare | 0.1× |
| HOWL Werewolf Therapeutics, Inc. | −4.8× |
| CRBU Caribou Biosciences, Inc. compare | −5.0× |
| HYPD Hyperion DeFi, Inc. compare | −8.4× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | −9.1× |
| LONA LeonaBio, Inc. compare | — |
| KLRS Kalaris Therapeutics Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets